<div id="readability-page-1"><p>Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for Context Therapeutics in a note issued to investors on Thursday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of $0.06 per share for the year, down from their prior forecast of $0.08. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.49) per share.</p><p>CNTX has been the topic of several other research reports. Piper Sandler raised their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, March 24th. Wall Street Zen lowered Context Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, March 29th. Guggenheim  restated a &#34;buy&#34; rating and set a $5.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Context Therapeutics in a research note on Monday, April 20th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a &#34;strong-buy&#34; rating in a research report on Monday, February 23rd. One investment analyst  has rated the stock with a Strong Buy rating, six have given a Buy rating and one  has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $6.60.</p><div><p><span></span><span>Get <strong>Context Therapeutics</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Report on Context Therapeutics</b></p><h2>Context Therapeutics Stock Performance</h2><p>Shares of NASDAQ:CNTX opened at $2.31 on Friday. The company has a fifty day moving average of $2.62 and a 200-day moving average of $1.90. The company has a market capitalization of $211.78 million, a PE ratio of -5.48 and a beta of 1.57. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62. </p><p>Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.03. </p><h2>Institutional Trading of Context Therapeutics</h2><p>Several institutional investors have recently made changes to their positions in the company. Sanctuary Advisors LLC bought a new stake in  Context Therapeutics during the first quarter worth $51,000.  Virtu Financial LLC purchased a new stake in shares of  Context Therapeutics during the fourth quarter worth $43,000.  XTX Topco Ltd boosted its stake in  Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company's stock worth $149,000 after purchasing an additional 91,008 shares during the period.  Quadrature Capital Ltd bought a new stake in shares of  Context Therapeutics during the fourth quarter valued at about $68,000.  Finally, Millennium Management LLC bought a new position in shares of  Context Therapeutics in the fourth quarter valued at approximately $3,824,000. Institutional investors own  14.03% of the company's stock. </p><h2>About Context Therapeutics</h2> (Get Free Report)<p>Context Therapeutics <span>NASDAQ: CNTX<span></span></span> is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.  </p><p>With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.</p><h2>See Also</h2><ul><li>Five stocks we like better than Context Therapeutics</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Context Therapeutics Right Now?</h2><p>Before you consider Context Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.</p><p>While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTX

LABU

<p>HC Wainwright has revised its FY2030 earnings per share estimate for Context Therapeutics Inc. (NASDAQ:CNTX) from $0.08 to $0.06. The consensus estimate for the company's current full-year earnings stands at ($0.49) per share. Various analysts have given mixed ratings on CNTX, with one Strong Buy, six Buy, and one Sell rating. The stock opened at $2.31, with a market cap of $211.78 million and a 52-week range of $0.49 to $3.62. Institutional investors hold 14.03% of the company's shares.</p>

What is HC Wainwright's Estimate for CNTX FY2030 Earnings?